Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort

BMJ Open

Volumn 7, Issue 1, 2017, Pages

  Bérard, Anick ^a,b   Zhao, Jin Ping ^a,b   Sheehy, Odile ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; ATRIOVENTRICULAR SEPTAL DEFECT; CHROMOSOME ABERRATION; COHORT ANALYSIS; COMORBIDITY; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DISEASE ASSOCIATION; EAR MALFORMATION; EYE MALFORMATION; FACE MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL MALFORMATION; HEART ATRIUM SEPTUM DEFECT; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NECK MALFORMATION; PERINATAL PERIOD; PREGNANT WOMAN; PRENATAL EXPOSURE; PREVALENCE; PUERPERAL DEPRESSION; RISK ASSESSMENT; SIDE EFFECT; CONGENITAL DISORDER; DEPRESSION; DRUG INDUCED MALFORMATION; INFANT; LONGITUDINAL STUDY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PROSPECTIVE STUDY; QUEBEC;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS; CONGENITAL ABNORMALITIES; DEPRESSION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; QUEBEC; SEROTONIN UPTAKE INHIBITORS;

EID: 85009460360     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013372     Document Type: Article

References (45)

1. CooperWO, WillyME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196: 544.e1-5.
2. Wichman CL, Fothergill A, Moore KM, et al. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol 2008;28: 714-16.
3. Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: Potential mechanisms for the observed associations. Reprod Toxicol 2011;32: 484-9.
4. Ciraulo DA, Shader RI. Pharmacotherapy of depression. 2nd edn. Springer, 2011: 34.
5. Louik C, Lin AE, Werler MM, et al. First-Trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356: 2675-83.
6. Alwan S, Reefhuis J, Rasmussen SA, et al., National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356: 2684-92.
7. Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin Epidemiol 2010;2: 29-36.
8. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80: 18-27.
9. Malm H. Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. Ther Drug Monit 2012;34: 607-14.
10. Berard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol 2015;212: 795. e1-12.
11. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370: 2397-407.
12. Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: A population-based cohort study. BJOG 2014;121: 1471-81.
13. Margulis AV, Abou-Ali A, Strazzeri MM, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: A propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 2013;22: 942-51.
14. Nordeng H, van Gelder MM, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012;32: 186-94.
15. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010;40: 1723-33.
16. Berard A, Sheehy O. The Quebec Pregnancy Cohort-prevalence of medication use during gestation and pregnancy outcomes. PLoS ONE 2014;9: E93870.
17. Vilain A, Otis S, Forget A, et al. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf 2008;17: 345-53.
18. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th edn. New York: Lippincott William & Wilkins, 2011.
19. Kulaga S, Zargarzadeh AH, Bérard A. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. BJOG 2009;116: 1788-95.
20. Jobin-Gervais K, Sheehy O, Berard A. Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy? Pharmacoepidemiol Drug Saf 2013;22: 155.
21. Blais L, Berard A, Kettani FZ, et al. Validity of congenital malformation diagnostic codes recorded in Quebec's administrative databases. Pharmacoepidemiol Drug Saf 2013;22: 881-9.
22. Lechat MF, Dolk H. Registries of congenital anomalies: EUROCAT. Environ Health Perspect 1993;101(Suppl 2): 153-7.
23. Lash TL, Fink AK. Semi-Automated sensitivity analysis to assess systematic errors in observational data. Epidemiology 2003;14: 451-8.
24. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol 2005;34: 1370-6.
25. Berard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: What is the evidence? Birth Defects Res Part A Clin Mol Teratol 2010;88: 171-4.
26. Yavarone MS, Shuey DL, Tamir H, et al. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993;47: 573-84.
27. Shuey DL, Sadler TW, Tamir H, et al. Serotonin and morphogenesis. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol (Berl) 1993;187: 75-85.
28. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003;21: 417-24.
29. Colvin L, Slack-Smith L, Stanley FJ, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res Part A Clin Mol Teratol 2011;91: 142-52.
30. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open 2012;2: Pii: E001148.
31. Wemakor A, Casson K, Garne E, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: A European register-based study. Eur J Epidemiol 2015;30: 1187-98.
32. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83: 68-76.
33. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-Analysis of epidemiological studies. Birth Defects Res Part A Clin Mol Teratol 2010;88: 159-70.
34. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design. BMJ 2015;350: H1798.
35. Bérard A, Iessa N, Chaabane S, et al. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-Analysis. Br J Clin Pharmacol 2016;81: 589-604.
36. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27: 607-13.
37. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981;58: 336-44.
38. Polen KN, Rasmussen SA, Riehle-Colarusso T, et al., National Birth Defects Prevention Study. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth Defects Res Part A Clin Mol Teratol 2013;97: 28-35.
39. De Jong van den Berg LT, Feenstra N, Sorensen HT, et al. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: Pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999;60: 33-6.
40. Nakhai-Pour HR, Broy P, Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182: 1031-7.
41. Einarson A, Choi J, Einarson TR, et al. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J Obstet Gynaecol Can 2009;31: 452-6.
42. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29: 918-26.
43. Zhao JP, Sheehy O, Bérard A. Regional variations in the prevalence of major congenital malformations in Quebec: The importance of fetal growth environment. J Popul Ther Clin Pharmacol 2015;22: E198-210.
44. Berard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol 2009;16: E360-9.
45. Swanson SA, Hernandez-Diaz S, Palmsten K, et al. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf 2015;24: 934-42.